Hematologic Malignancies. Eunice S. Wang MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine
|
|
- Homer Brown
- 6 years ago
- Views:
Transcription
1 Hematologic Malignancies Eunice S. Wang MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine
2
3
4 Blood cancers are normal blood cells gone bad Jordan C et al. N Engl J Med 2006;355:
5 Hierarchy of Hematopoiesis
6 Types of Blood Cancers Myeloid Leukemia Acute (AML) Chronic (CML) Myelodysplasia (MDS) Myeloproliferative (MPD) Polycythemia vera Thrombocythemia Lymphoid Leukemia Acute (ALL) Chronic (CLL) Lymphoma Non-Hodgkin (NHL) Hodgkin (HL/HD) Multiple myeloma (MM)
7 Diagnosis of blood cancers 1. Appearance (morphology) Protein Cancer cell X X Protein 4. Specific gene mutations 2. Abnormal protein expression (flow cytometry) (histochemistry) 3.Chromosome abnormalities (cytogenetics)
8 Treatments for Blood Cancers Cytotoxic chemotherapy Stem cell (bone marrow) transplantation Biological therapies (some experimental) Receptor tyrosine kinase inhibitors Antibodies Immunomodulating agents Differentiating agents
9 Hematopoietic Stem Cell Transplantation Stem cell source: - Allogeneic, autologous, syngeneic, - Marrow vs. blood vs. cord blood cells Conditioning regimens (prepare BM) Immunologic consequences -Graft vs. host, Graft vs leukemia
10
11
12 Autologous Stem Cell Transplant= Means for High dose Chemotherapy
13 Allogeneic Stem Cell Transplant= Immune/Blood System Replacement
14 Acute leukemias Leukemia is cancer of the white blood cellscancer in one of its most explosive, violent incarnations Its pace, its acuity, its breathtaking, inexorable arc of growth forces rapid, often drastic decisions; it is terrifying to experience, terrifying to observe, and terrifying to treat. The body invaded by leukemia is pushed to its brittle physiological limit.. Siddartha Mukherjee (The Emperor of Maladies)
15
16 Acute myeloid leukemia (AML) Immature myeloid blasts Auer rods (coalesced granules)
17 Acute myeloid leukemia (AML): Clinical features Most common acute leukemia in adults (median age 65 yrs) Rapidly growing disease over days-weeks Presents with infection, bleeding or bruising, fatigue due to high or low white blood cell counts, low hemoglobin and low platelets May arise from prior hematologic disease such as myelodysplasia, myeloproliferative disorders, or prior chemotherapy/radiation for other cancers
18 AML: Diagnosis Morphology: increased numbers of immature myeloid blood cells in blood/marrow (M1-M7) Cytogenetics: most important prognostic factor for AML (new classification system) Gene mutations: One third of AML have FLT3 gene mutation associated with chemotherapy resistance and early relapse Flow cytometry: Majority of AML express CD33 protein
19 AML: Poor Prognosis Unfavorable cytogenetics (most important) Age > 65 years old Low performance status Prior hematologic disorder Therapy-related AML High white blood cell count at diagnosis
20 Overall AML survival by cytogenetics Slovak ML et al Blood 2000: 96: , 2000
21 Standard AML therapy Induction: Admission to hospital for inpatient chemotherapy with two drugs: cytarabine (7 days) and anthracycline (3 days); requires a 30 day inpatient stay for chemo, antibiotics, transfusions until normal blood counts recover Remission= absence of leukemia on BM; does not equal cure (disease gone forever) All Pts in remission will require consolidation chemotherapy (1-4 shorter rounds of chemotherapy) OR stem cell transplantation for long term cure
22 AML: Allogeneic Stem Cell Transplantation HLA matched donor (sibling vs unrelated) Only cure for pts (generally <55 yo) High risk leukemia Refractory to initial chemotherapy Relapsed leukemia Second remission after relapse Mortality/morbidity with SCT: 25-30%
23 Flt-3 kinase receptor signaling FLT-3 kinase activation in hematopoietic cells results in stimulation of myriad downstream ( PI3K, ras, Stat) pathways promoting growth
24 FLT3 Mutations in AML Result in constitutive activation of FLT3 kinase Activation of growth-related signaling pathways FLT3 inhibitors (CEP-701, PKC412, MLN518, SU4516) block receptor kinase activity
25 FLT3 mutations in AML are associated with worse outcomes Frequency CR Rate* ITDs 71 (32%) 65% Asp835 Mutations 32 (14%) 82% *vs. 76% DFS OS p =.03 p =.0004 Frohling, et al., Blood 2002;100:4372
26 Acute promyelocytic leukemia (APL) APL is characterized by the malignant proliferation of immature promyelocytes.. the blood fills up with these toxin-loaded promyelocytes. Moody, mercurial, and jumpy, the cells of APL can release their poisonous granules on a whim- precipitating massive bleeding or simulating a septic reaction in the body Most cancers contain cells that refuse to stop growing. In APL, the cancer cells also refuse to grow up. Siddartha Mukherjee (The Emperor of Maladies)
27
28 Acute promyelocytic leukemia (APL) APL cells contain a translocation between chr 15 & 17 (here seen by FISH)
29 APL: PML/RAR-alpha Fusion Protein Balanced Translocation between Chr 15 and 17 Results in a maturation arrest of cells at the promyelocyte stage Warrell R et al. N Engl J Med 1993;329:
30 APL Therapy: Chemotherapy + Differentiation Therapy Immature APL cell Retinoic Acid (ATRA, Vesanoid) t(15;17) Arsenic Mature normal WBC
31 Arsenic treatment for APL
32 Chronic Myeloid Leukemia (CML)
33
34 Chronic Myeloid Leukemia (CML) Elevated neutrophils in all stages of maturation
35 CML is defined by presence of t(9;22) Philadelphia chromosome
36 Translocation (9;22) results in aberrant BCR-ABL protein 9 9 q+ 22 Ph ( or 22q-) bcr bcr-abl abl FUSION PROTEIN WITH TYROSINE KINASE ACTIVITY
37 Detection of bcr-abl by FISH Interphase Metaphase Courtesy of Charles Sawyers, UCLA.
38 Natural history of CML disease Chronic phase Accelerated phase Advanced phases Blast crisis Median 5 6 years stabilization Median duration 6 9 months Median survival 3 6 months Accelerated and blast phase CML cells represent transformation to acute leukemia states
39 CML therapy BCR-ABL tyrosine kinase inhibitors - Imatinib mesylate (Gleevec, formerly STI571) - Dasatinib (Sprycel) - Nilotinib (Tasigna) Allogeneic stem cell transplantation (SCT) IFN-alpha, chemotherapy: hydroxyurea
40 Mechanism of Action of BCR-ABL and Inhibition by Imatinib (Gleevec)
41 Survival and Progression to the Accelerated Phase of CML Patients Receiving Imatinib Druker B et al. N Engl J Med 2006;355:
42 Mechanism of Resistance to imatinib (Gleevec) in CML cells
43 Mutations in BCR-ABL kinase leading to imatinib resistance in CML cells
44 Second generation BCR-ABL inhibitors
45 Chronic myeloid leukemia (CML) Before the year 2000, when we saw patients with CML, we told them they had a very bad disease, that their course was fatal, their prognosis was poor with a median survival of maybe 3-6 years.. Today when I see a patients with CML, I tell them that the disease is an indolent leukemia with an excellent prognosis, that they will usually live their functional life span provided they take an oral medicine, Gleevec, for the rest of their lives. Siddartha Mukherjee (The Emperor of Maladies)
46 Other Myeloproliferative neoplasms
47
48 JAK2 signaling in MPN
49 Role of JAK2 in MPN biology
50 Jakafi (JAK2 inhibitor) in MPN
51 Myelodysplastic syndrome (MDS)
52 Myelodysplastic syndrome (MDS) Clonal hematopoietic stem cell diseases characterized by dysplasia and ineffective hematopoiesis in 1+ myeloid lineages Pancytopenia Infections, bleeding complications Transfusion dependence Risk of transformation to AML
53
54 Myelodysplastic Syndrome Hypomethylating agents 5-azacytidine (Vidaza ) Decitabine (Dacogen ) Supportive care: transfusions, growth factors Allogeneic stem cell transplantation
55 Hypomethylating Agents
56 Hypomethylating agents improve transfusion needs
57 Vidaza treatment Improves MDS survival Proportion Surviving months Log-Rank p= HR = 0.58 [95% CI: 0.43, 0.77] Deaths: AZA = 82, CCR = 113 Difference: 9.4 months 50.8% 24.4 months 26.2% Time (months) from Randomization CCR AZA Fenaux P et al. Lancet Oncology 10: , March 2009.
58 Lenalidomide for MDS therapy Derivative of thalidomide, a morning sickness pill associated with birth defects Effective for therapy of MDS with chromosome 5 abnormality Inhibits interactions between MDS cells and the local microenvironment
59 Acute Lymphoblastic Leukemia (ALL) Clonal expansion of immature lymphoblasts
60
61 Acute Lymphoblastic Leukemia (ALL) 75% occur in children < 6 yrs old Comprise a minority of acute leukemia in adults B cell > T cell lineage Frequently involves central nervous system, lymph nodes, spleen, liver, and gonads Cytogenetic prognostic groups: Hyperdiploidy (51-65 chromosomes): GOOD Ph chromosome t (9;22): POOR MLL gene t(4;11): POOR
62 Improvement in Pediatric ALL survival 1962 to 2005 Pui C and Evans W. N Engl J Med 2006;354:
63 Clinical trial results in adult vs. pediatric ALL patients Pui C et al. N Engl J Med 2004;350:
64 ALL: Multiple alternating drugs for up to two years Induction: cyclophosphamide, daunorubicin, vincristine, high dose steroids, L-asparaginase 70-80% CR Consolidation: high dose cytarabine and methotrexate Central nervous system therapy: radiation or chemotherapy given via spinal taps Maintenance: Oral 6-MP + methotrexate for 18 months
65 ALL: Allogeneic Stem Cell Transplantation HLA matched donor (sibling vs unrelated) Indicated for young pts <50 yo High risk cytogenetics (Ph chromosome) High WBC at diagnosis (>100K) Central nervous system disease Disease refractory to initial chemotherapy Relapsed disease
66 Adult ALL associated with Ph chromosome t(9;22) benefit from Gleevec 9 9 q+ 22 Ph ( or 22q-) bcr bcr-abl abl FUSION PROTEIN WITH TYROSINE KINASE ACTIVITY
67 Bcr-abl inhibition may also improve outcomes of Ph+ ALL patients
68 Improved clinical outcomes of Ph+ ALL with addition of imatinib to standard chemotherapy Improved clinical outcomes of Ph+ ALL with addition of imatinib to standard chemotherapy
69 Antibody based therapies for B-cell ALL Blinatumomab Anti-CD19 Rituximab (Rituxan ) Anti-CD20 CD19 CD20 B-cell ALL CD22 Anti-CD22 Immunotoxin CAT-8015 (HA22) CD52 Alemtuzumab (Campath ) Anti-CD52
70 Chronic Lymphocytic Leukemia (CLL) Clonal expansion of mature lymphocytes
71
72 CLL: Diagnosis Morphology: elevated numbers of mature lymphoid cells in the blood and bone marrow Flow cytometry: B-cell (CD5+ CD19+ CD20+) ZAP70 protein is associated with more rapid disease progression Molecular: Immunoglobulin H (IgH) mutations are associated with outcomes Cytogenetics: Associated with prognosis
73 CLL: Clinical features Patients of older age (median 70 yrs) Indolent slow growing disease (usually) Survival is stage-specific Presents with high white blood cell count, enlarged spleen and lymph nodes, anemia, and low platelets Associated with immune dysfunction Autoimmune mediated low counts
74 CLL: Therapy Multiple rounds of combination outpatient chemotherapy with antibodies chlorambucil, fludarabine steroids Antibodies Radiation to large lymph node sites Stem cell Transplantation Experimental therapies
75 Antibody therapies for CLL Antibodies against CD52 (Campath) and CD20 (Rituxan) markers expressed on CLL cells have anti-leukemia effects alone Studies are testing the effects of combining antibody therapy with chemotherapy Side effects: Allergic reactions, depletion of normal white cells leads to unusual virus infections
76 Ritixumab (Anti-CD20 Antibody) therapy for B-cell CLL
77 CLL Therapy: Revlimid (lenalidomide)
78 Lymphoma: cancers of the immune cells in lymph node and lymphatics Fifth most common cancer in the USA Two types: 1.Hodgkin disease (HD) 2. Non-Hodgkin lymphoma (NHL)
79
80 Lymphoma: Diagnosis Over 40 different types of lymphoma!!! Hodgkin- 4 types Non-Hodgkin- 40+ types Lymph node biopsy - Morphology (small vs large cell) - Pattern: Diffuse vs follicular - Flow cytometry: B vs. T cell
81
82 Lymphoma: Disease Staging Staging of disease - Bone marrow biopsies (both sides) - CT/PET/Gallium scans - Spinal tap (for high risk disease)
83 Lymphoma: Stages I: Single lymph node or extra-lymphatic site (IE) II: 2 or more lymph node regions on the same side of the diaphragm or localized involvement of an extra-lymphatic site (IIE) III: Lymph node regions on both sides of the diaphragm or localized involvement of an extra-lymphatic organ or site (IIIE) or spleen (IIIS) or both (IIISE) IV: Diffuse or disseminated involvement of one or more extralymphatic organs with or without associated lymph node involvement "A" for asymptomatic or "B" for constitutional symptoms.
84 Lymphoma: Stages I-IV
85 Hodgkin Lymphoma (HL) Age peaks and 50+ yrs Incidence 2.9/100,000 in USA Multi-agent chemotherapy effective for most patients Five year survival >80% (Not 100%) Refractory/relapsed to transplant Reed Sternberg Cell in HL
86 Non-Hodgkin Lymphoma (NHL): Indolent (low grade) Multiple painless enlarging nodes Wide spread disease including BM Slow growth over many years Long survival but largely incurable despite many therapies May be observed without treatment May progress to aggressive lymphoma
87 NHL: Aggressive (high grade) Single rapidly growing mass Disease outside of the lymph nodes is common Grows quickly with symptoms arising from large tumor volumes Responds well and can sometimes be cured by combination high-dose chemotherapy and radiation to involved sites
88 NHL: Poor prognostic factors Age > 55 years Low Performance status Advanced Stage of disease (III-IV) Presence of extranodal sites Elevated LDH (lactic dehydrogenase), a blood test indicating increased tumor cells
89 Non Hodgkin Lymphoma (NHL): Subtypes defined by cytogenetics Follicular lymphoma: Abnormal bcl-2 protein- t (14;18) Burkitt lymphoma: Abnormal c-myc protein- t (8;14) Mantle cell lymphoma: Abnormal bcl-1/ cyclin D1- t (11;14)
90 Aggressive B cell NHL: Therapy Multiple cycles of anti-cd20 antibody (rituxumab) and chemotherapy (cyclophosphamide, doxorubicin, vincristine, steroids) Radiation to focal extranodal sites For refractory/relapsed disease: - Radioisotopes conjugated to CD20 antibody - Hematopoietic stem cell transplant - Experimental therapies
91 Anti-CD20 antibody therapies for non-hodgkin lymphoma Rituxan (anti-cd20) CD20 CD20 NHL CD20 CD20 Bexxar Zevalin Radioactive isotopoes
92 Multiple myeloma
93
94 Multiple myeloma (MM) Neoplasm of PLASMA CELLS (Immunoglobulin secreting terminally differentiated end-stage B cells in BM) Older patients, increased in African Americans Associated with bone pain, anemia, high calcium Clinically can be smouldering to aggressive disease
95 MM: Bony lytic lesions OSTEOLYTIC lesions with skeletal lesions and pathological fractures
96 MM Diagnosis: Serum protein electrophoresis Discovery of a serum M-component or monoclonal protein spike is suggestive of a clonal plasma cell disorder.
97 Multiple Myeloma Therapy Prevention of end-organ damage, fractures Management of symptomatic myeloma or radiographic evidence of bone disease Chemotherapy, steroids Radiation to painful bony lesions Proteosome inhibitors, thalidomide Autologous/Allogeneic stem cell transplantation
98 Types of Blood Cancers Myeloid Leukemia Acute (AML) Chronic (CML) Myelodysplasia (MDS) Myeloproliferative (MPD) Polycythemia vera Thrombocythemia Lymphoid Leukemia Acute (ALL) Chronic (CLL) Lymphoma Non-Hodgkin (NHL) Hodgkin (HL/HD) Multiple myeloma (MM)
99 Questions?? Questions??
Acute Leukemia Diagnosis
Acute Leukemia Diagnosis Elizabeth A. Griffiths, MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine 3 841,390 843,820 Blood cancers are normal blood cells
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationa resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationWBCs Disorders 1. Dr. Nabila Hamdi MD, PhD
WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features
More informationPathology of Hematopoietic and Lymphoid tissue
CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationForm 2011 R4.0: Acute Lymphoblastic Leukemia (ALL) Pre-HCT Data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: - - HCT type: (check all that apply) Autologous Allogeneic,
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More informationMS.4/ Acute Leukemia: AML. Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD
MS.4/ 27.02.2019 Acute Leukemia: AML Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising
More informationPathology of Hematopoietic and Lymphoid tissue
Pathology of Hematopoietic and Lymphoid tissue Peerayut Sitthichaiyakul, M.D. Department of Pathology and Forensic Medicine Faculty of Medicine, Naresuan University CONTENTS White blood cells and lymph
More information7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationTreating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS
Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationFacts LEUKEMIA LYMPHOMA MYELOMA
Facts 2009-2010 Table of Contents Figures 1 Executive Summary 3 About Blood Cancer Therapy Drug and Radiation Therapy Stem Cell Transplantation Quality of Life Survivorship 7 Leukemia Living with Leukemia
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationJeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ
Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase
More informationDone By : WESSEN ADNAN BUTHAINAH AL-MASAEED
Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Acute Myeloid Leukemia Firstly we ll start with this introduction then enter the title of the lecture, so be ready and let s begin by the name of Allah : We
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationDisclosures/COI. Cases in Hematopathology. Outline. Heme Path Findings Not to Miss. Normal Peripheral Smear 6/30/2016
Disclosures/COI Cases in Hematopathology Vamsi Kota Assistant Professor Department of Hematology & Medical Oncology Leukemia/BMT I have no disclosures or conflicts of interest regarding this presentation.
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More informationUPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationBeyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure
Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationCIBMTR Center Number: CIBMTR Recipient ID: Today s Date: Date of HSCT for which this form is being completed:
Chronic Myelogenous Leukemia (CML) Post-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic,
More informationLeukemias and Lymphomas Come From Normal Blood Cells
Leukemias and Lymphomas Come From Normal Blood Cells by Steve Anderson, Ph.D. Steve Anderson has a Ph.D. in Immunology with 25 years experience in biomedical research. His scientific expertise includes
More informationTHE LEUKEMIAS. Etiology:
The Leukemias THE LEUKEMIAS Definition 1: malignant transformation of the pluripotent stem cell, successive expansion of the malignant clone from the bone marrow to the tissues Definition 2: Heterogenous
More informationHAEMATOLOGICAL MALIGNANCY
HAEMATOLOGICAL MALIGNANCY Reference Compulsory reading Haematology at Glance 2 nd ed. Atul Mehta & Victor Hoffbrand Chapters: 20 to 31 Pages: 46 to 69 Pathogenesis of Haematological Malignancy Figure (a)
More informationBLOOD AND LYMPH CANCERS
BLOOD AND LYMPH CANCERS 2 Blood and Lymph Cancers Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Kenneth C. Anderson, MD Harvard Medical School and Dana-Farber
More informationAcute Myeloid Leukemia: A Patient s Perspective
Acute Myeloid Leukemia: A Patient s Perspective Patrick A Hagen, MD, MPH Cardinal Bernardin Cancer Center Loyola University Medical Center Maywood, IL Overview 1. What is AML? 2. Who gets AML? Epidemiology
More informationMS.4/ 1.Nov/2015. Acute Leukemia: AML. Abdallah Abbadi
MS.4/ 1.Nov/2015. Acute Leukemia: AML Abdallah Abbadi Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising and hemorrhagic spots on her trunk
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationTransplants for MPD and MDS
Transplants for MPD and MDS The question is really who to transplant, with what and when. Focus on myelofibrosis Jeff Szer Royal Melbourne Hospital Myelodysplasia Little needs to be said Despite new therapies
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationHighlights from the 2017 Annual Meeting of the American Society of Hematology
Latest NEWS IN BLOOD CANCER RESEARCH Highlights from the 2017 Annual Meeting of the American Society of Hematology CancerCare Connect Booklet Series www.cancercare.org The CancerCare Connect Booklet Series
More informationLeukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College
Leukemias Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College Introduction Leukaemias are malignant disorders of the haematopoietic stem cell compartment,
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationWBCs Disorders. Dr. Nabila Hamdi MD, PhD
WBCs Disorders Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features and
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationForm 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data
Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Research ID: Event date: - - HCT type: (check all that apply)
More information1 Introduction. 1.1 Cancer. Introduction
Introduction 1 1.1 Cancer 1 Introduction Cancer is the most precarious disease characterized by uncontrolled proliferation of cells without any physiological demands of the organism. Cancer may be defined
More informationCHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009
LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationHematologic Malignancies. Kim Noonan, RN, ANP, AOCN
Hematologic Malignancies Kim Noonan, RN, ANP, AOCN Hematologic Malignancies Cancers that affect blood, bone marrow and lymphatic system. Liquid tumors vs solid tumors Leukemia Lymphoma Multiple Myeloma
More informationMyelodysplastic Syndrome: Let s build a definition
1 MDS: Diagnosis and Treatment Update Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian Hospital Myelodysplastic
More informationMyelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More information2011: ALL Pre-HCT. Subsequent Transplant
2011: ALL Pre-HCT The Acute Lymphoblastic Leukemia Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific pre-hct data such as: the recipient s hematologic and cytogenetic
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationMyelodyplastic Syndromes Paul J. Shami, M.D.
Myelodyplastic Syndromes Paul J. Shami, M.D. Professor of Hematology, University of Utah Member, Huntsman Cancer Institute Objectives Define Myelodysplastic Syndromes (MDS) Explain how MDS are diagnosed
More information2013 Pathology Student
About this guide If you re reading this introduction, it means you are probably either a) covering hematopathology in your pathology class right now, or b) studying for boards. Either way, you ve come
More informationLymphoma and Myeloma Kris3ne Kra4s, M.D.
Lymphoma and Myeloma Kris3ne Kra4s, M.D. Hematologic Malignancies Leukemia Malignancy of hematopoie3c cells Starts in bone marrow, can spread to blood, nodes Myeloid or lymphoid Acute or chronic Lymphoma
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationAdult Acute leukemia. Matthew Seftel. August
Adult Acute leukemia Matthew Seftel August 21 2007 mseftel@cancercare.mb.ca Principles 3 cases Diagnosis and classification of acute leukemia (AL) Therapy Emergencies Remission induction BMT Complications
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationNeoplastic proliferation arising from white blood cells. Introductory remarks. Classification
Neoplastic proliferation arising from white blood cells Lymphoproliferative and myeloproliferative diseases and syndromes Oliver Rácz, 2012-2017 1 Introductory remarks Leukemia and lymphoma are old descriptive
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationSystematic Reviews in Hematological Malignancies
Systematic Reviews in Hematological Malignancies Pia Raanani, MD Davidoff Cancer Center Rabin Medical Center, Israel 1 2 Disorder CHMG Systematic review* Title Protocol Full Review Myelodysplastic syndrome
More informationMatthew Ulrickson, MD Banner MD Anderson Cancer Center September 12, 2017
Matthew Ulrickson, MD Banner MD Anderson Cancer Center September 12, 2017 Discuss the clinical presentation and diagnosis of acute leukemia * Discuss the impact of molecular features on prognosis and management
More informationMyelodysplastic Syndromes (MDS) Diagnosis, Treatments & Support
Myelodysplastic Syndromes (MDS) Diagnosis, Treatments & Support LLS Mission & Goals Our mission. Cure leukemia, lymphoma, Hodgkin s disease and myeloma, and improve the quality of life of patients and
More informationLow grade High grade , immune suppression chronic persistent inflammation viruses B-symptoms
We've one category for lymphoid neoplasm which is the lymphoma in contrast to that of myeloid which has three categories; acute myeloid leukemias, myeloproliferative & myelodysplastic disorders. Lymphoma
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationMYELOPROLIFARATIVE NEOPLASMS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin).
MYELOPROLIFARATIVE NEOPLASMS Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin). These are a group of chronic conditions characterised by clonal proliferation of marrow precursor cells. PRV, essential thrombocyathaemia,
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationHENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Part 4 MYELOID NEOPLASMS
HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD Part 4 MYELOID NEOPLASMS Introduction: o Myeloid neoplasms are divided into three major categories: o Acute
More informationMECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA. April 16, 2008
MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA April 16, 2008 FACULTY COPY GOAL: Learn the appearance of normal peripheral blood elements and lymph nodes. Recognize abnormal peripheral blood
More informationCorrespondence should be addressed to Anas Khanfar;
Case Reports in Oncological Medicine, Article ID 949515, 4 pages http://dx.doi.org/10.1155/2014/949515 Case Report Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion
More informationClassification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationCase #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...
Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR
More informationMyelodysplastic Syndromes: Everyday Challenges and Pitfalls
Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Kathryn Foucar, MD kfoucar@salud.unm.edu Henry Moon lecture May 2007 Outline Definition Conceptual overview; pathophysiologic mechanisms Incidence,
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationRelapsed acute lymphoblastic leukemia. Lymphoma Tumor Board. July 21, 2017
Relapsed acute lymphoblastic leukemia Lymphoma Tumor Board July 21, 2017 Diagnosis - Adult Acute Lymphoblastic Leukemia (ALL) Symptoms/signs include: Fever Increased risk of infection (especially bacterial
More informationLymphomas and multiple myeloma 12/23/2018 1
60 Lymphomas and multiple myeloma 12/23/2018 1 Lymphomas Lymphoma is cancer of the lymphatic system. Lymphomas are subdivided into two main categories: Hodgkin's lymphoma (HL) and non- Hodgkin's lymphoma
More informationCharles Mxxx DCEM2 Toulouse Purpan Medical School 01/26/2012 ECN Item 162
Charles Mxxx DCEM2 Toulouse Purpan Medical School 01/26/2012 ECN Item 162 Definition Pathophysiology Clinical signs and symptoms Biology and Diagnosis Different types of AL Prognosis and Treatment Malignant
More informationDisclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory
More information